Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin

American Journal of Surgical Pathology

Volumn 29, Issue 4, 2005, Pages 452-459

  Clarke, Loren E ^a,b   Bayerl, Michael G ^a   Bruggeman, Richard D ^a   Mauger, David ^a   Ioffreda, Michael D ^a   Abou Elella, Ashraf ^a   Helm, Klaus F ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Caspase; CD30 positive lymphoproliferative disorders; FADD; Lymphomatoid papulosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CASPASE 3; CD30 ANTIGEN; DEATH RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALE; NICK END LABELING; PROTEIN EXPRESSION; REED STERNBERG CELL; REMISSION; SKIN BIOPSY; SYSTEMIC DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; APOPTOSIS; BIOPSY; CASPASE 3; CASPASES; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LYMPHOMA, LARGE-CELL, KI-1; LYMPHOMATOID PAPULOSIS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 15744392301     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000155154.46434.93     Document Type: Article

References (55)

1. Aoki M, Niimi Y, Takezaki S, et al. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. Br J Dermatol. 2001;145:123-126.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
3. Assaf C, Hummel M, Dippel E, et al. Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas. Br J Haematol. 2003;120:488-491.
4. Barrett KL, Willingham JM, Garvin AJ, et al. Advances in cytochemical methods for detection of apoptosis. J Histochem Cytochem. 2001;49:821-832.
5. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.
6. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
7. Beylot-Barry M, Groppi A, Vergier B, et al. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood. 1998;91:4668-4676.
8. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591-3598.
9. Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996; 106:696-700.
10. DeCoteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437-3441.
11. Dempsey PW, Doyle SE, He JQ, et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193-209.
12. Drexler HG, Gignac SM, von Wasielewski R, et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533-1559.
13. Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003;199:221-228.
14. Duckett CS, Gedrich RW, Gilfillan MC, et al. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17:1535-1542.
15. Gedrich RW, Gilfillan MC, Duckett CS, et al. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996;271:12852-12858.
16. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem. 2002;50:449-454.
17. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1-4.
18. Gruss HJ, Boiani N, Williams DE, et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994; 83:2045-2056.
19. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 2002;21:2493-2503.
20. Jaffe ES, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Lyon, France: IARC Press, 2001.
21. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40:244-256.
22. Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci. 2001;941:59-68.
23. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001;61:3330-3338.
24. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. 2002; 29:295-300.
25. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol. 1997;133:829-833.
26. Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood. 2003;101:1487-1493.
27. Levi E, Wang Z, Petrogiannis-Haliotis T, et al. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol. 2000;115:1034-1040.
28. Liang X, Smoller BR, Golitz LE. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders. J Cutan Pathol. 2002;29:459-464.
29. Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049-1058.
30. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol. 2003;163:1687-1698.
31. Marcelli M, Cunningham GR, Walkup M, et al. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 1999;59:382-390.
32. McCarty MJ, Vukelja SJ, Sausville EA, et al. Lymphomatoid papulosis associated with Ki-1-positive anaplastic large cell lymphoma: a report of two cases and a review of the literature. Cancer. 1994;74:3051-3058.
33. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000; 96:4307-4312.
34. Mon M, Manuelli C, Pimpinelli N, et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: a clue to the pathophysiology of clinical regression. Blood. 1999;94:3077-3083.
35. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1995;267:316-317.
36. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
37. Nevala H, Karenko L, Vakeva L, et al. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145:928-937.
38. Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol. 1998;29:1223-1230.
39. Rassidakis GZ, Jones D, Lai R, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol. 2003;200:240-248.
40. Rassidakis GZ, Jones D, Thomaides A, et al. Apoptotic rate in peripheral T-cell lymphomas: a study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol. 2002;118:328-334.
41. Schiemann WP, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood. 1999;94:2854-2861.
42. Sigel JE, Hsi ED. Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L. Mod Pathol. 2000;13:446-451.
43. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res. 2000;301:19-31.
44. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
45. ten Berge RL, Meijer CJ, Dukers DF, et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood. 2002;99:4540-4546.
46. Tourneur L, Mistou S, Michiels FM, et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene. 2003;22:2795-2804.
47. Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86:1240-1245.
48. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 2003;63:8563-8572.
49. Weaver KD, Yeyeodu S, Cusack JC Jr, et al. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol. 2003;61:187-196.
50. Wellmann A, Otsuki T, Vogelbruch M, et al. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood. 1995;86:2321-2328.
51. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973-980.
52. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
53. Wood GS, Hardman DL, Boni R, et al. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood. 1996;88:1765-1770.
54. Yamabe K, Shimizu S, Ito T, et al. Cancer gene therapy using a proapoptotic gene, caspase-3. Gene Ther. 1999;6:1952-1959.
55. Zackheim HS, Jones C, Leboit PE, et al. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am Acad Dermatol. 2003;49:620-623.